Evidence map›Paper›PMID 24785961›Full record

ReviewCurrent opinion in lipidology2014

High-density lipoprotein metabolism, composition, function, and deficiency.

Ernst J Schaefer, Pimjai Anthanont, Bela F Asztalos

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in lipidology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.International journal of molecular sciences · 2021
    Review
  13. Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function.International journal of molecular sciences · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2016
    Article
  18. How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ernst J SchaeferLipid Metabolism Section, Cardiovascular Nutrition Laboratory, Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA.
Pimjai Anthanont
Bela F Asztalos
Tufts University · US

Funding

MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCYR01HL060935 · NHLBI · TUFTS UNIVERSITY BOSTON · PI SCHAEFER, ERNST JOHN · 1999 to 2009
$2.2M
NHLBI NIH HHS R01 HL060935
6 · The paper itself

Abstract

purpose of reviewTo examine the recent advances in our knowledge of HDL metabolism, composition, function, and coronary heart disease (CHD), as well as marked HDL deficiency states because of mutations in the apolipoprotein (apo) A-I, ATP-binding cassette transfer protein A1 and lecithin cholesterol acyltransferase (LCAT) gene loci. RECENT

findingsIt has been documented that apoA-I, myeloperoxidase and paraoxonase 1 (PON1) form a complex in HDL that is critical for HDL binding and function. Myeloperoxidase has a negative impact on HDL function, whereas PON1 has a beneficial effect. Patients who lack apoA-I develop markedly premature CHD. Patients who lack ATP-binding cassette transfer protein A1 transporter function have only very small discoidal preβ-1 HDL, and develop hepatosplenomegaly, intermittent neuropathy and premature CHD, although significant heterogeneity for these disorders has been reported. Patients with LCAT deficiency have abnormal small discoidal LDLs and HDL particles, and develop kidney failure. Enzyme replacement therapy is being developed for the latter disorder. SUMMARY: Recent data indicates that proteins other than apoA-I and apoA-II such as MPO and PON1 have important effects on HDL function. There has been considerable recent progress made in our understanding of HDL protein content and function.

Indexed as

AnimalsApolipoprotein A-IAryldialkylphosphataseCoronary DiseaseGenetic LociHumansHypoalphalipoproteinemiasLipoproteins, HDLPeroxidasePhosphatidylcholine-Sterol O-AcyltransferaseApolipoprotein A-IAryldialkylphosphataseLipoproteins, HDLPeroxidasePhosphatidylcholine-Sterol O-AcyltransferasePON1 protein, human

Identifiers

PMID24785961
PMCPMC5489068
OpenAlexW1989508919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.